Welcome to BioSeeker Group!

Triple Analysis: Colorectal Cancer, Lung Cancer and Protein Kinase Inhibitors

Additional Information

Published Date May 1, 2012
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 5319
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Colorectal Cancer, Lung Cancer and Protein Kinase Inhibitors in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Lung Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Colorectal Cancer, Lung Cancer and Protein Kinase Inhibitors.

    To find out more about Triple Analysis: Colorectal Cancer, Lung Cancer and Protein Kinase Inhibitors, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Colorectal Cancer, Lung Cancer and Protein Kinase Inhibitors is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Lung Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Colorectal Cancer
The colorectal cancer report part comprises defined and up to date development strategies for 347 colorectal cancer drugs within the portfolio of 182 investigators, from Ceased to Marketed. This part extensively analyses their 210 identified drug targets, organized into 205 drug target strategies, and assesses them in eight different compound strategies in colorectal cancer.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market

Part II: Lung Cancer
The lung cancer report part comprises defined and up to date development strategies for 416 lung cancer drugs within the portfolio of 218 investigators, from Ceased to Marketed. This part extensively analyses their 241 identified drug targets, organized into 237 drug target strategies, and assesses them in eight different compound strategies and and three subindications of lung cancer.
This part is based on the following publication:
Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market

Part III: Protein Kinase Inhibitors
The protein kinase drug report part comprises defined and up to date development strategies for 648 drugs in oncology within the portfolio of 212 companies world-wide, from Ceased to Marketed. The report extensively analyses their 183 identified drug targets, organized into 278 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Colorectal Cancer
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Colorectal Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (210 Drug Targets) 32-451
7 Emerging New Products to Established Ones: Drug Target Strategies of Colorectal Cancer Drugs by their Highest Stage of Development (205 Drug Target Strategies and 347 Colorectal Cancer Drugs) 452-699
8 Compound Strategies at Work: Competitive Benchmarking of Colorectal Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-745
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Colorectal Cancer Drug Pipeline by Investigator (182 Companies) 746-1,039
10 Disclaimer 1040
11 Drug Index 1041
12 Company Index 1050
Figures: Includes 6 Figures
Tables: Includes 242 Tables
Total Number of Pages: 1,056

Part II: Lung Cancer
5.1 The Scope of this Report 31
6 Consider the Therapeutic Target Among Lung Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (241 Drug Targets) 35-526
7 Emerging New Products to Established Ones: Drug Target Strategies of Lung Cancer Drugs by their Highest Stage of Development (237 Drug Target Strategies and 416 Lung Cancer Drugs) 527-817
8 Compound Strategies at Work: Competitive Benchmarking of Lung Cancer Drugs by Compound Strategy (8 Compound Strategies) 818-870
9 Selecting Subindication for Lung Cancer Drugs (Three Subindications of Lung Cancer) 871-898
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lung Cancer Drug Pipeline by Investigator (218 Companies) 899-1299
11 Disclaimer 1300
12 Drug Index 1301
13 Company Index 1314
Figures: Includes 7 Figures
Tables: Includes 284 Tables
Total Number of Pages: 1323

Part III: Protein Kinase Inhibitors
5.1 The Scope of this Report 38
6 Consider the Therapeutic Target Among Protein Kinase Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (183 Drug Targets) 42-516
7 Emerging New Products to Established Ones: Drug Target Strategies of Protein Kinase Drugs in Oncology by their Highest Stage of Development (278 Drug Target Strategies and 648 Drugs) 517-945
8 Compound Strategies at Work: Competitive Benchmarking of Protein Kinase Cancer Drugs by Compound Strategy (8 Compound Strategies) 946-1013
9 Selecting Indication for Protein Kinase Drugs in Oncology (70 Cancer Indications) 1014-1223
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Protein Kinase Drug Pipeline in Oncology by Investigator (212 Investigators and 648 Drugs) 1224-2939
11 Disclaimer 2940
Figures: Includes 8 Figures
Tables: Includes 389 Tables
Total Number of Pages: 2,940

This Report Includes the Following Companies:
4SC
A&G Pharmaceutical
AB Science
Abbott
Abiogen
Acceleron Pharma
ACT Biotech
Active Biotech
Adherex
Advanomics
Advantagene
Advenchen
AEgera
AEterna Zentaris
Affimed Therapeutics
Agennix
Aida Pharmaceuticals
Alchemia
Alder Biopharmaceuticals
Alethia Biotherapeutics
Allist Pharmaceuticals
Allos Therapeutics
Allostera
Alnylam
AlphaVax
Alseres Pharmaceuticals
Altor BioScience
Ambit Biosciences
Amgen
Amphora
Anavex Life Sciences
AngioChem
Ansaris
Antisense Pharma
Antisoma
Anza Therapeutics
Apogee Biotechnology
ApopLogic Pharmaceuticals
Apotex
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Astellas
Astex Pharmaceuticals
AstraZeneca
AVEO
AVI BioPharma
Avila Therapeutics
Axelar
Bavarian Nordic
Bayer
Benitec
Berkeley Lab
Betapharma
Bio-Path Holdings
BioAlliance Pharma
BioAxone
Biocompatibles
Biogen Idec
Biokine Therapeutics
BioLineRx
Bionovo
BioNumerik
BioSante
Biotecnol
Biotica Technology
BioVex
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
Callisto Pharmaceuticals
Cambrex
Can-Fite BioPharma
CanBas
Cancer Advances
Cancer Research Technology
Catalyst Biosciences
Celator Pharmaceuticals
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Celleron
Cellmid
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CerRx
CG Therapeutics
ChemGenex Pharmaceuticals
Chemokine Therapeutics
Chong Kun Dang
Choongwae
Chroma Therapeutics
Circadian Technologies
Clavis Pharma
Cleveland BioLabs
Clinical Data
CLL Pharma
CompleGen
Compugen
CoNCERT Pharmaceuticals
Coronado Biosciences
Cosmo Pharmaceuticals
Critical Outcome Technologies
CuraGen
Curaxis
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytokine PharmaSciences
Cytokinetics
Cytopia
CytRx
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Debiopharm
Deciphera Pharmaceuticals
Dendreon
DeveloGen
DiaMedica
Dong-A
Dyax
Dynavax Technologies
ECI
EGEN Inc
Eisai
Elara Pharmaceuticals
Eli Lilly
Endocyte
Enkam Pharmaceuticals
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Erimos
Etubics
Exelixis
FasTrack Pharmaceuticals
Fresenius
Galapagos
Galena Biopharma
Gemin X Biotechnologies
Generex
Genmab
Genta
GenVec
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
GlobeImmune
GlycoGenesys
GPC Biotech
Gradalis
Green Cross
Hanmi
Heidelberg Pharma
Hoffmann-La Roche
Human Genome Sciences
Hutchison China MediTech
Hypha Discovery
Idera Pharmaceuticals
IkerChem
ImClone Systems
ImmunoCellular Therapeutics
Immunocore
ImmunoFrontier
ImmunoGen
Immunomedics
ImmuPharma
Incozen Therapeutics
Incyte Corporation
Infinity Pharmaceuticals
Inhibiton Therapeutics
InNexus Biotechnology
Innovive
Inovio
Insmed
Insys Therapeutics
Intellikine
Intezyne Technologies
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
ISU ABXIS
Ivy Medical Chemicals
Jennerex Biotherapeutics
Jina Pharmaceuticals
Johnson & Johnson
Kadmon
KAI Pharmaceuticals
KaloBios
Kalypsys
Karus Therapeutics
Keryx Biopharmaceuticals
Kiadis
Kinex
Kirin Pharma
KuDOS
Kyowa Hakko Kirin
Labopharm
Leo
Lexicon Pharmaceuticals
Ligand
Lorus Therapeutics
MacroGenics
Marillion Pharmaceuticals
Marina Biotech
MaxoCore Pharmaceuticals
Meda
MediGene
Medisyn Technologies
Menarini
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mirna Therapeutics
Mitsubishi Tanabe Pharma
Molecular LogiX
MolMed
Mologen
Mycenax
Myrexis
Nano Terra
Nektar Therapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurocrine Biosciences
NewSouth Innovations
NexusPharma
NicOx
Nidus Laboratories
NIH
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Novacea
NovaLead
Novartis
Novogen
Nycomed Pharma
Oasmia
Oncalis
OncoGenex Pharmaceuticals
OncoMed
Onconova
OncoTherapy Science
Oncothyreon
Oncozyme Pharma
Onyvax
Orca Therapeutics
Orchestra Therapeutics
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Paladin Labs
PanaGin
Pathway Therapeutics
PBL Therapeutics
Peregrine Pharmaceuticals
Pfizer
Pharmaclon
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Philogen
Phoenix Biotechnology
PHusis Therapeutics
Pieris
Pierre Fabre
Piramal
PIramed
Plexxikon
Portola Pharmaceuticals
POZEN
Pro-Pharmaceuticals
Proacta
Progen Pharmaceuticals
Progenics Pharmaceuticals
Protherics
Provid
QLT
Quantum Pharmaceuticals
Ras Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
RESprotect
Rexahn
Rigel
Samtheo Biopharma
Samyang
Sanofi
Sanofi-Aventis
Santaris Pharma
Sareum
SBI Biotech
SBIO
Scancell
Schering-Plough
Seattle Genetics
Selvita
Semafore Pharmaceuticals
Sentinel Oncology
SGX Pharmaceuticals
ShimodaAtlantic Oncology
Shire
Sigma-Tau
Silence Therapeutics
Simcere Pharmaceuticals
Sirnaomics
Spirogen
SRI International
Sunesis
SuperGen
Supratek Pharma
Swedish Orphan Biovitrum
Switch Pharma
Symphogen
SynDevRx
Synta Pharmaceuticals
Taiho
Takeda
Talon Therapeutics
Tamir Biotechnology
Tapestry Pharmaceuticals
Targa Therapeutics
TargeGen
Targepeutics
Tau Therapeutics
TauTaTis
Taxolog
TCD Pharma
Tekmira Pharmaceuticals
Telik
Teva
Thallion Pharmaceuticals
The Genetics Company
Therion Biologics
Theryte
ThromboGenics
Tigris Pharmaceuticals
Titan Pharmaceuticals
ToolGen
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
TransTech Pharma
TriAct Therapeutics
Trion Pharma
UCB
Valeant
VasGene Therapeutics
Vaxon Biotech
VaxOnco
Velacor Therapeutics
Vernalis
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
VioQuest Pharmaceuticals
Viralytics
ViroMed
Wyeth
Xcovery
Xencor
Xerion
Xoma
Yakult Honsha
YM BioSciences
Zenyaku Kogyo
Zhejiang Beta Pharma
Zivena
A Shortlist of Drugs Included are:
AC-480
AE-37
AF-802
afatinib
aflibercept
alvocidib
AMG-386
amrubicin hydrochloride
Angiozyme
apatinib
AR-42
ARQ-197
astuprotimut-r
AT-7519
AT-9283
axitinib
AZD-8055
AZD-8931
bafetinib
barasertib
bardoxolone methyl
belagenpumatucel-L
belotecan hydrochloride
bevacizumab
BEZ-235
BGT-226
BI-811283
BIBF-1120
BMS-690514
BMS-754807
BMS-777607
bosutinib
brivanib alaninate
Cabozantinib
CAL-101
canfosfamide hydrochloride
capecitabine
catumaxomab
CBP-501
CC-223
cediranib
celecoxib
cetuximab
crizotinib
dacomitinib
danusertib
dasatinib
dinaciclib
docetaxel
dovitinib lactate
doxifluridine
E-75
emepepimut-S
endostatin
endoxifen
ENMD-2076
enzastaurin hydrochloride
erlotinib
etoposide (1)
etoposide phosphate
everolimus
foretinib
fostamatinib disodium
gefitinib
GSK-2118436
IC-83
icotinib hydrochloride
icrucumab
idronoxil
imatinib mesilate
INCB-028060
iniparib
INSM-18
interferon (gamma1b)
interferon gamma
irinotecan bead
irinotecan hydrochloride
JI-101
KD032
KX2-391
lapatinib ditosylate
lenvatinib
lestaurtinib
linifanib
linsitinib
LY-2090314
masitinib
MGCD-265
MGN-1703
midostaurin
MK-1775
MKC-1
MLN-8237
MM-111
motesanib diphosphate
MVA-BN Her-2 vaccine
nadroparin
necitumumab
neratinib
nilotinib
nimotuzumab
NPB-001-056
oblimersen sodium
ON-01910
onartuzumab
OSI-027
OTS-102
P276-00
paclitaxel
paclitaxel polyglumex
panitumumab
pazopanib hydrochloride
PD-0332991
pegdinetanib
pemetrexed disodium
perifosine
PHA-848125AC
plitidepsin
ponatinib
PX-866
quinacrine
quizartinib dihydrochloride
RAF-265
raltitrexed
ramucirumab
regorafenib
ridaforolimus
rilotumumab
ruxolitinib
RX-0201-N
SCH-900776
seliciclib
sirolimus
sorafenib tosylate
ß-lapachone
SU-6668
sunitinib malate
talactoferrin alfa
talmapimod
tandutinib
tegafur + uracil
tegafur + uracil + leucovorin
telatinib
temsirolimus
terameprocol
thymalfasin
tivozanib
topotecan
triciribine phosphate
TS-1
vandetanib
varlitinib
vemurafenib
volasertib
vosaroxin
XL-147
XL-281
XL-413
XL-647
XL-765

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Colorectal Cancer, Lung Cancer and Protein Kinase Inhibitors.
    To find out more about Triple Analysis: Colorectal Cancer, Lung Cancer and Protein Kinase Inhibitors, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Colorectal Cancer, Lung Cancer and Protein Kinase Inhibitors is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Pancreatic Cancer, Apoptosis and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in Pancreatic Cancer and by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors. Learn More


Triple Analysis: Breast Cancer, Prostate Cancer and Peptides
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Prostate Cancer and by the compound strategy of Peptides. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Breast Cancer, Melanoma and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Melanoma and by the mechanism/target/effect of Cancer Vaccines. Learn More


Triple Analysis: Melanoma, Prostate Cancer and Antibodies
This triple analysis focuses on cancer drug development strategies in both Melanoma and Prostate Cancer and by the compound strategy of Antibodies. Learn More